Sign In to Request a Protocol
Sign In to Request a Protocol

Tirzepatide (15 mg Vial)

  • Table of Contents

Tirzepatide Dosage Chart

Tirzepatide is dosed at 2.5 mg–10 mg weekly via subcutaneous injection in educational protocols. A 15 mg vial reconstituted with bacteriostatic water yields about 7.5 mg/mL. This information is for research and educational use only.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.
  • Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
  • Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 75 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety.

  • Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (2 mL = 7.5 mg/mL)

PhaseWeekly Dose (mg)Units (per injection) (mL)
Weeks 1–42.5 mg33 units (0.33 mL) × 1 injection
Weeks 5–85 mg67 units (0.67 mL) × 1 injection
Weeks 9–127.5 mg100 units (1.0 mL) × 1 injection
Weeks 13–1610 mg67 units (0.67 mL) × 2 injections

Frequency: Inject once weekly subcutaneously on the same day each week. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

  • 1 . Draw 2.0 mL bacteriostatic water with a sterile syringe.
  • 2 . Inject slowly down the vial wall; avoid foaming.
  • 3 . Gently swirl until dissolved (do not shake).
  • 4 . Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F),  protected from light.
  • 5 . Use within 28 days of reconstitution.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Product Details

Plan based on an 8–16 week protocol with gradual titration (once‑weekly dosing).

  • Peptide Vials (Tirzepatide, 5 mg each):
  • 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 2 vials
  • 12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 4 vials
  • 16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 7 vials
  • Insulin Syringes (U‑100, 1 mL):
  • 8 weeks: 8 syringes (1/week)
  • 12 weeks: 12 syringes (1/week)
  • 16 weeks: 20 syringes (1/week wks 1–12, 2/week wks 13–16)
  • Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
  • 8 weeks (2 vials): 4 mL → 1 × 10 mL bottles
  • 12 weeks (4 vials): 8 mL → 1 × 10 mL bottles
  • 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
  • Per week: 2 swabs (1 injection day)
  • 8 weeks: 16 swabs → recommend 1× 100-count boxes
  • 12 weeks: 24 swabs → recommend 1 × 100-count box
  • 16 weeks: 32 swabs → recommend 1 × 100-count box
  • Protocol Overview

Concise summary of the once‑weekly regimen.

  • Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
  • Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
  • Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.
  • Reconstitution: 2.0 mL per 15 mg vial (7.5 mg/mL) for manageable injection volumes.
  • Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
  • Dosing Protocol

Suggested weekly titration approach.

  • Start: 2.5 mg once weekly for 4 weeks (initiation dose)
  • Escalate: Increase by 2.5 mg every 4 weeks as tolerated.
  • Maintenance: 5–15 mg weekly based on response and tolerability.
  • Frequency: Once per week (subcutaneous), same day each week.
  • Timing: Any time of day; with or without food; rotate injection sites.
  • Storage Instructions

Proper storage preserves peptide quality and efficacy.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution
  • Shelf life: Use reconstituted solution within 28 days
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • For multi‑injection doses, use different sites for each injection on the same day.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document weekly dose, date, and injection site to maintain consistency.
  • Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.
  • How This Works

Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration.

  • Potential Benefits & Side Effects

Observations from clinical trials and published literature.

Potential Benefits:

  • Glycemic control: Significant HbA1c reductions in type 2 diabetes trials
  • Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).
  • Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
  • Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence
  • Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
  • Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
  • Prioritize protein to preserve lean mass during weight loss.
  • Combine resistance training and aerobic activity to support metabolic health.
  • Stay hydrated, especially given potential gastrointestinal effects.
  • Prioritize sleep and stress management to support adherence and recovery.
  • Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
  • Dispose of needles and syringes in a sharps container immediately after use.
  • Important Note

This content is for educational purposes only and is not medical advice.

  • References

StatPearls (NCBI Bookshelf)

— Farzam K, Patel P. Tirzepatide. StatPearls Publishing; 2024. Comprehensive overview of pharmacology, dosing, and clinical use.
More Info

Frontiers in Endocrinology

— Gallwitz B. GIP/GLP-1 receptor agonist Tirzepatide for type 2 diabetes and obesity. Front Endocrinol. 2022;13:1004044.
More Info

The Lancet

— Frias JP, et al. Efficacy and safety of LY3298176 (Tirzepatide), a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (Phase 2 trial). Lancet. 2018;392(10160):2180-2193.
More Info

New England Journal of Medicine

— Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
More Info

FDA Prescribing Information

— Mounjaro (Tirzepatide) injection Prescribing Information. Eli Lilly and Company; 2022.
More Info

GobyMeds Pharmacy

— Does Compounded Tirzepatide Need To Be Refrigerated? Storage guidelines for reconstituted peptides.
More Info

CDC Injection Safety

— Preventing Unsafe Injection Practices. Guidelines for multi-dose vials and safe needle disposal.
More Info

MedlinePlus Medical Encyclopedia

— Subcutaneous (SQ) injections: Technique, site rotation, and best practices.
More Info

Mayo Clinic

— Tirzepatide (Subcutaneous route) – Drugs and Supplements. Clinical overview and patient information.
More Info

CDC Vaccine Administration

— Subcutaneous injection technique: angle, site selection, and no aspiration guidance.
More Info